Advertisement
open access
Medical Conferences

Medical Conferences

  • Conference Reports
    • 2023 Medicom Conference Planning
  • Conference Proceedings
  • Disease Areas
  • Other Medical News
  • Media
    • Podcast
    • Video
    • Education
  • About
    • Conference Proceedings
    • Vacancies

Tag: ruxolitinib

New developments in steroid-refractory acute GvHD

Presented By
Prof. Ronjon Chakraverty, University of Oxford, UK
Conference
EBMT 2023

15 June, 2023 16:54

As-needed ruxolitinib shows successful long-term symptom control in AD

Presented By
Dr Andrew Blauvelt, Oregon Medical Research Center, OR, USA
Trial
Phase 3, TRuE-AD1 and TRuE-AD2
Conference
AAD 2023

15 May, 2023 11:43

Vitiligo patients maintain re-pigmentation after ruxolitinib cream withdrawal

Presented By
Prof. John Harris, UMass Chan Medical School, MA, USA
Conference
AAD 2023

15 May, 2023 10:51

The rise of JAK inhibitors for alopecia areata

Presented By
Dr Brett King, Yale University, CT, USA
Conference
DDD 2023

10 May, 2023 13:47

Ruxolitinib mediates clonal evolution of RAS pathway mutations in MPN

Presented By
Dr Nabih Maslah, Université Paris Cité, France
Conference
ASH 2022

20 February, 2023 12:43

Enhancing re-pigmentation rates with topical ruxolitinib in all body areas

Presented By
Prof. Thierry Passeron, University Côte d’Azur, France
Trial
Phase 3, TRuE-V1; TRuE-V2
Conference
EADV 2022

5 November, 2022 10:50

JAK inhibitors may offer a new horizon in the treatment of sarcoidosis

Presented By
Prof. William Damsky, Yale School of Medicine, USA
Conference
AAD 2022

17 May, 2022 11:12

Light at the end of the tunnel for vitiligo therapy

Presented By
Dr David Rosmarin, Tufts Medical Center, USA
Trial
Phase 3, TRuE-V1; TRuE-V2
Conference
AAD 2022

17 May, 2022 11:05

AAD 2022 Highlights Podcast

Presented By
Dr Rachel Giles, Medicom
Conference
AAD 2022

14 April, 2022 11:02

Topical JAK1/JAK2 inhibitor effective in vitiligo

Presented By
Dr David Rosmarin, Tufts Medical Center Boston, USA
Trial
Phase 3, TRuE-V1; TruE-V2
Conference
EADV 2021

18 November, 2021 13:27

Ruxolitinib cream: a safe treatment for elderly AD patients

Presented By
Prof. Jacek Szepietowksi, Wroclaw Medical University, Poland
Trial
Phase 3, TRuE-AD1; TRuE-AD2
Conference
EADV 2021

18 November, 2021 13:21

Novel targets in myelofibrosis: overview of emergent therapies

Presented By
Prof. Francesco Passamonti, University of Insubria, Italy
Trial
PERSIST; SIMPLIFY; BOREAS
Conference
EHA 2021

5 August, 2021 14:54

Allergies: an underrated factor in alopecia pathogenesis

Presented By
Prof. Natasha Mesinkovska, UC Irvine School of Medicine, CA, USA
Conference
AAD VMX 2021

7 June, 2021 13:45

Ruxolitinib improves steroid-refractory aGVHD across subtypes

Presented By
Prof. Robert Zeiser, University Hospital Freiburg, Germany
Trial
Phase 3, REACH2
Conference
EHA 2020

9 September, 2020 09:57

Topical ruxolitinib effective in vitiligo

Presented By
Prof. Amit Pandya, University of Texas Southwestern Medical Center, USA
Conference
EADV 2019

9 December, 2019 13:08

JAK inhibitors: a new therapeutic tool for dermatologists

Presented By
Prof. Brett King, Yale School of Medicine, USA
Conference
AAD 2019

19 April, 2019 20:08

Can JAK inhibitors close the current therapeutic gap in AD?

Presented By
Prof. Eric Simpson, Oregon Health & Science University, USA
Conference
AAD 2019

19 April, 2019 14:12

JAK-inhibitors: an emerging treatment option for vitiligo

Presented By
Prof. John Harris, University of Massachusetts, USA
Conference
AAD 2019

19 April, 2019 13:53
site created by:   

© 2023 Medicom Medical Publishers.  All rights reserved. Terms and Conditions | Privacy Policy